Urinary Bladder Cancer malady

MedlinePlus: The bladder is a hollow organ in your lower abdomen that stores urine. bladder cancer occurs in the lining of the bladder. it is the sixth most common type of cancer in the united states. symptoms include blood in your urine a frequent urge to urinate pain when you urinate low back pain smoking is a major risk factor for bladder cancer. exposure to certain chemicals in the workplace is another. people with a family history of bladder cancer or who are older, white or male have a higher risk. treatments for bladder cancer include surgery, radiation, chemotherapy and biologic therapy. biologic therapy, or immunotherapy, boosts your body's own ability to fight cancer. nih: national cancer institute²³

MalaCards: Urinary Bladder Cancer, also known as bladder cancer, is related to tongue cancer and nasopharynx carcinoma. An important gene associated with Urinary Bladder Cancer is CCND1 (cyclin D1), and among its related pathways are Signal transduction_PTEN pathway and Transcription P53 signaling pathway. The drugs mitomycin and prednisone and the compounds threonine and crcs have been mentioned in the context of this disorder. Affiliated tissues include the urinary bladder, kidney and lung, and related mouse phenotypes are respiratory system and craniofacial.

Disease Ontology: An urinary system cancer that results in malignant growth located in the urinary bladder.⁶

Genetics Home Reference: Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).¹⁷

Wikipedia: Bladder cancer is any of several types of malignancy arising from the epithelial lining (i.e., the...⁴⁴ more...

OMIM: 109800

Aliases & Descriptions:

urinary bladder cancer 6 44 17 8 bladder cancer 6 7 44 17 33 32 23 malignant tumor of urinary bladder 44 17 cancer of the bladder 44 17 tumor of the bladder 6

carcinoma of bladder 43 malignant neoplasms 43 bladder neoplasm 43 bladder tumors 32 neoplasms 43

Diseases related to urinary bladder cancer by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1524)

id	Related Disease	Score	Top Affiliating Genes
1	tongue cancer	33.9	CDKN1A, CDH1, MMP2, MMP9, FLT1
2	nasopharynx carcinoma	33.1	VEGFA, RASSF1, CDKN2A, CDH1, MMP9, CCND1
3	vulva cancer	32.1	TP53, KRT20, EGFR
4	salivary gland cancer	32.1	BIRC5, MMP9, CASP3, ERBB2, NOS2, EGFR
5	oral cavity cancer	32.0	NAT2, VEGFA, BAX, GSTM1, ERBB2, TP53
6	colonic neoplasm	31.6	CLU, CDKN1A, CD44, CDH1, TP53
7	parathyroid carcinoma	31.3	RB1, MKI67, CCND1, TP53, TERT
8	ovarian cancer	31.1	RB1, CHEK2, CDKN1A, CDKN2B, CDKN1B, CDKN2A
9	bronchogenic carcinoma	30.9	JUN, ENO2, CYP1A1, KRT19
10	thyroid cancer	30.8	BRAF, TP63, TERT, KRT20, KRT19
11	brain cancer	30.6	VEGFA, BAX, ENO2, HRAS, EGFR
12	bladder cancer susceptibility	30.4	NAT2, XRCC1, GSTM1, GSTP1, ERCC2, EGFR
13	myoma	30.1	PCNA, FGF2, CCND1, ERCC2, TERT, PTGS2
14	intraepithelial neoplasm	30.1	PCNA, XRCC1, CDKN2A, MKI67, ERBB2, TP53
15	squamous cell carcinoma	30.0	SERPINB3, CD44, CDH1, MKI67, GSTP1, CCND1
16	cardia cancer	30.0	XRCC1, CDKN2A, CD44, GSTM1, GSTP1, MDM2
17	fallopian tube carcinoma	30.0	MYC, CDKN1B, MKI67, ERBB2, TP53
18	intestinal neoplasm	29.8	BRAF, MMP2, MMP9, PTGS2
19	pancreatic cancer	29.5	VEGFA, BIRC5, CDKN1A, MGMT, MAPK1, CCND1
20	neuroendocrine tumor	29.5	RASSF1, MKI67, ENO2, IGF1R, KRT8, KRT20
21	bladder urothelial papillary carcinoma	29.5	BIRC5, CDKN2B, CDH1, MKI67, GSTP1, CASP3
22	stomach carcinoma	29.4	RASSF1, CDKN2A, CD44, CDH1, CCND1, PLAU
23	malignant peripheral nerve sheath tumor	29.3	CDKN2A, CD44, MDM2, TERT, EGFR, TOP2A
24	cervix carcinoma	29.2	MYC, CDKN1A, CDKN2A, CD44, MKI67, FGFR3
25	basal cell carcinoma	29.1	BAX, XRCC1, XRCC3, CD44, MKI67, GSTM1
26	multiple myeloma	29.0	CD44, FN1, FGFR3, CCND1, ABCB1
27	mesenchymal cell neoplasm	28.9	PCNA, CD44, CCND1, CASP3, HRAS
28	mixed cell type cancer	28.8	ENO2, ERBB2, TP53, KRT20
29	familial pancreatic cancer	28.8	BRAF, CHEK2, CDKN2A, ERBB2, TP53, SPINK1
30	bladder carcinoma in situ	28.7	UPK2, PTCRA, NOS2, ELAVL3
31	lynch syndrome	28.7	BRAF, CD44, MKI67, MGMT, PTGS2
32	skin benign neoplasm	28.7	BRAF, XPC, JUN, MGMT, FGFR3, MAPK1
33	myelodysplastic syndrome	28.7	BIRC5, CHEK2, CDKN2B, GSTM1, FGFR1, TERC
34	anaplastic carcinoma	28.6	BRAF, CDH1, ENO2, TP63, KRT8, KRT20
35	familial colorectal cancer	28.4	BRAF, CHEK2, CDKN2A, CDH1, MGMT, GSTM1
36	craniopharyngioma	28.4	PCNA, RARB, MKI67, IGF1R, ERBB2, TP53
37	pancreatic ductal carcinoma	28.4	VEGFA, CDKN2A, MMP9, IL1B, TP53, NOS2
38	male breast cancer	28.4	PCNA, CHEK2, ERBB2, TP53, SP1, CTSD
39	diffuse gastric cancer	28.3	XRCC3, CDH1, GSTM1, GSTP1, ERCC2, ERBB2
40	large cell carcinoma	28.3	BAX, ENO2, TP53, TP63, KRT19, EGFR
41	chronic lymphocytic leukemia	28.3	BIRC5, BAX, CD27, CDKN2B, CDK4, IL2
42	cholecystitis	28.2	PCNA, MKI67, TP53, EGF, EGFR
43	xeroderma pigmentosum	28.1	PCNA, RARG, BAX, XRCC1, XRCC3, XPC
44	ovarian mucinous neoplasm	28.1	PCNA, RB1, BRAF, MYC, CHEK2, CDKN1A
45	prostate carcinoma	28.0	NAT2, VEGFA, CDH1, MMP9, GSTM1, ERBB2
46	oligodendroglioma	27.9	BRAF, CDKN2B, CDKN2A, MGMT, EGFR
47	kidney cancer	27.8	BRAF, VEGFA, RARB, RASSF1, CD44, GSTP1
48	embryonal cancer	27.6	FGF2, EGF, TGFA
49	dna topoisomerase ii	27.6	PCNA, MYC, JUN, CDKN1A, MKI67, GSTP1
50	prostatic hypertrophy	27.5	PCNA, CD36, GSTP1, FGF2, KLK3, EGF

Clinical features from OMIM: 109800

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 bacillus calmette-guerin vaccine, carboplatin, cisplatin, cisplatin pwdr [va product], dexamethasone, dexamethasone acetate, dexamethasone acetate pwdr [va product], dexamethasone phosphate, dexamethasone sodium phosphate, dexamethasone sodium phosphate pwdr [va product], doxorubicin, doxorubicin hydrochloride, doxorubicin hydrochloride liposome, etoposide, etoposide phosphate, linolenic acid, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, mitomycin, prednisolone, prednisolone acetate, prednisolone acetate pwdr [va product], prednisolone pwdr [va product], prednisolone sodium phosphate, prednisolone tebutate, prednisone, prednisone pwdr [va product], thiotepa, valrubicin

MalaCards organs/tissues related to urinary bladder cancer:

²²

FMA organs/tissues related to urinary bladder cancer:

¹¹

MGI Mouse Phenotypes related to urinary bladder cancer:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.7	CHD2, TP63
2	craniofacial phenotype	MP:0005382	10.0	TACC3, SP1, IGF1R, MAPK8, RARG
3	endocrine/exocrine gland phenotype	MP:0005379	10.0	FGFR1, ARHGDIB, CDKN1B, CDKN2B, CHD2, RARG
4	other phenotype	MP:0005395	9.4	NOS2, PTGS2, IL2, FN1, CDKN2A, CLU
5	hematopoietic system phenotype	MP:0005397	9.2	GAPDH, WNT1, FGFR3, FGF2, ARHGDIB, CDK4
6	liver/biliary system phenotype	MP:0005370	8.8	POU5F1, TACC3, ABCB1, EGFR, TP53, HYAL1
7	embryogenesis phenotype	MP:0005380	8.8	TACC3, EGFR, KRT19, KRT8, CTTN, SP1
8	renal/urinary system phenotype	MP:0005367	8.6	SKP2, DAPK1, TP63, HRAS, GLI1, CASP3
9	pigmentation phenotype	MP:0001186	8.4	ERCC2, TP53, TERC, KRT1, EGFR, CASP3
10	normal phenotype	MP:0002873	8.2	E2F3, POU5F1, PSCA, TACC3, HINT1, FLT1
11	limbs/digits/tail phenotype	MP:0005371	8.2	IGF1R, GLI1, GJB2, ERBB2, TP63, TERC
12	immune system phenotype	MP:0005387	8.2	EGFR, CCND1, IL2, FGFR3, FGFR1, ARHGDIB
13	no phenotypic analysis	MP:0003012	7.9	GLI1, HRAS, GJB2, TP53, PTGS2, CYP1A1
14	hearing/vestibular/ear phenotype	MP:0005377	7.5	IGF1R, CASP3, GJB2, PLAU, NFKB1, EGFR
15	adipose tissue phenotype	MP:0005375	7.2	TERC, PTGS2, PLAU, NOS2, EGFR, TGFA
16	behavior/neurological phenotype	MP:0005386	6.8	TACC3, ABCB1, NFKB1, NOS2, PLAUR, CTSD
17	integument phenotype	MP:0010771	6.8	E2F3, GJB2, HRAS, IFNG, IGF1R, CCND1
18	reproductive system phenotype	MP:0005389	6.5	ARHGDIB, NAT1, FLT1, FN1, MMP9, CDH1
19	mortality/aging	MP:0010768	6.3	GAPDH, CTSD, SPINK1, SP1, TP53, TRIO
20	skeleton phenotype	MP:0005390	6.1	WNT1, TGFA, TYMP, EGFR, KRT19, NFKB1
21	nervous system phenotype	MP:0003631	5.8	POU5F1, TGFB1, TYMP, EGFR, KRT19, PLAUR
22	digestive/alimentary phenotype	MP:0005381	5.2	ERBB2, CDKN1A, CEACAM1, RARB, RARG, MYC
23	growth/size phenotype	MP:0005378	5.1	CCND1, CDKN1A, JUN, XPC, XRCC1, BAX
24	muscle phenotype	MP:0005369	4.6	MDM2, CHD2, CLU, RARB, MYC, VEGFA
25	tumorigenesis	MP:0002006	4.6	KRT19, CCND1, CCNE1, MAPK8, MDM2, IL2
26	vision/eye phenotype	MP:0005391	4.5	E2F3, TGFB1, TGFA, EGFR, EGF, NOS2
27	homeostasis/metabolism phenotype	MP:0005376	3.0	SKP2, NFKB1, NOS2, PLAUR, PLAU, CTSD
28	cardiovascular system phenotype	MP:0005385	2.7	TP53, IL1B, FGFR1, FGF2, FLT1, FN1
29	cellular phenotype	MP:0005384	2.7	TRIO, IL2, IL1RN, FGFR3, FGFR1, FGF2

Articles related to urinary bladder cancer:

(show top 50)    (show all 99)

id	Title	Authors	Year	Affiliating Genes
1	Nitrative DNA damage and Oct3/4 expression in urinary bladder cancer with Schistosoma haematobium infection. (21951846)	Ma N.... Kawanishi S.	2011	POU5F1
2	Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. (20627335)	Gangwar R.... Mittal R.D.	2011	PTGS2
3	A polymorphism of the POLG2 gene is genetically assoc iated with the invasiveness of urinary bladder cancer in Japanese males. (21734712)	Ratanajaraya C.... Matsuda F.	2011	POLG2
4	A sequence variant at 4p16.3 confers susceptibility t o urinary bladder cancer. (20348956)	Kiemeney L.A.... Stefansson K.	2010	FGFR3, MYC, TP63
5	Rs710521[A] on chromosome 3q28 close to TP63 is assoc iated with increased urinary bladder cancer risk. (21063684)	Lehmann M.L.... Golka K.	2010	TP63
6	Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in adv anced tumors in an ethnic Kashmiri population. (21156242)	Pandith A.A.... Siddiqi M.	2010	TP53
7	Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen. (18828023)	Chen L.... Li X.	2009	HINT1, COTL1
8	Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. (19489682)	Ahirwar D.K.... Mittal R.D.	2009	TGFB1, IL1B, IFNG
9	Sequence variant on 3q28 and urinary bladder cancer r isk: findings from the Los Angeles-Shanghai bladder case-control study. (19843673)	Stern M.C.... Cortessis V.K.	2009	TP63
10	Susceptibility to urinary bladder cancer: relevance o f rs9642880[T], GSTM1 0/0 and occupational exposure. (19801959)	Golka K.... Hengstler J.G.	2009	GSTM1
11	Genetic variation in the prostate stem cell antigen g ene PSCA confers susceptibility to urinary bladder cancer. (19648920)	Wu X.... Gu J.	2009	PSCA
12	Urinary bladder cancer producing granulocyte-colony stimulating factor: a case report and review of the literature (19175000)	Yoshino T.... Yoneda K.	2008	CSF3
13	Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. (18367114)	Ecke T.H.... Loening S.A.	2008	TP53
14	Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells. (18468578)	Lee S.J.... Moon S.K.	2008	MAPK1, MAPK8, CDKN1B
15	Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. (18801463)	Lee S.J.... Moon S.K.	2008	MMP9, NFKB1
16	Heat shock protein expression independently predicts survival outcome in schistosomiasis-associated urinary bladder cancer. (19199268)	El-Meghawry El-Kenawy A.... Hasan M.S.	2008	HSPB1
17	Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer (18799038)	Pu X.Y.... Wang X.H.	2008	KRT20
18	Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. (18514770)	Gkialas I.... Lykourinas M.	2008	KRT19, SPINK1
19	TP53 gene mutations as an independent marker for urinary bladder cancer progression. (18425359)	Ecke T.H.... Schlechte H.H.	2008	TP53
20	Focus on urinary bladder cancer markers: a review. (18923360)	Ecke T.H.	2008	FGFR3, ERBB2, BIRC5
21	Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. (18288642)	Harris L.D.... Grossman H.B.	2008	LCP1
22	Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. (17899426)	Kolla S.B.... Kumar R.	2008	ERBB2
23	Impaired gap junction formation and intercellular calcium signaling in urinary bladder cancer cells can be improved by GAP6976. (17957529)	Leinonen P.... Peltonen J.	2007	GJB2
24	P53 mutations in urinary bladder cancer patients from Central Poland. (17495352)	Borkowska E.... Kal/uzewski B.	2007	TP53
25	N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. (16550165)	Hein D.W.	2006	NAT2
26	Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. (16505106)	Mohammed S.I.... Knapp D.W.	2006	PTGS2
27	Novel blood biomarkers of human urinary bladder cancer. (16740760)	Osman I.... Liew C.C.	2006	CTSD, IGFBP7, CHD2
28	Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. (16734859)	Takihana Y.... Takeda M.	2006	TERT, TERC
29	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. (16010419)	Wild P.J.... Hartmann A.	2005	PTGS2
30	Identification of differentially expressed proteins during human urinary bladder cancer progression. (15936593)	Memon A.A.... Yoo Y.J.	2005	IDH1, PRDX2
31	TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. (15215162)	Zheng M.... Schraml P.	2004	TRIO
32	The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. (15082007)	Tzai T.S.... Chow N.H.	2004	TP53, RB1, CDKN2A
33	E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. (15122326)	Oeggerli M.... Sauter G.	2004	E2F3
34	Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. (12594816)	Chan M.W.... To K.F.	2003	RASSF1
35	HER-2 and TOP2A coamplification in urinary bladder cancer. (14566826)	Simon R.... Sauter G.	2003	ERBB2, TOP2A
36	p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay. (12725329)	Goudopoulou A.... Davaris P.S.	2003	TP53
37	Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. (11971182)	Simon R.... Sauter G.	2002	CDK4, MDM2, GLI1
38	Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. (11839665)	Chan M.W.... To K.F.	2002	GSTP1, CDH1, DAPK1
39	Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. (11872630)	Wang L.... Kato T.	2002	CCND1
40	p53 mutations in urinary bladder cancer. (11384101)	Berggren P.... Hemminki K.	2001	TP53
41	Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. (10569545)	SA!nchez-Carbayo M.... Soria F.	1999	KRT1
42	Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. (10398139)	Wagner U.... Sauter G.	1999	CCND1
43	Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. (10569622)	Suzuki T.... Fujioka T.	1999	TEP1
44	Expression of epidermal growth factor receptor in urinary bladder cancer metastases. (9537579)	Bue P.... MalmstrAPm P.U.	1998	EGFR
45	High levels of transforming growth factor-alpha (TGF-alpha) mRNA may predict local relapses in early stage urinary bladder cancer. (9797711)	Gazzaniga P.... Agliano A.M.	1998	TGFA
46	Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. (9117215)	Tsuji M.... Kagawa S.	1997	TP53, MKI67
47	The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. (9521509)	Korkolopoulou P.... Thomas-Tsagli E.	1997	MDM2, EGFR, PCNA
48	Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. (7915094)	Lee S.E.... Lin S.N.	1994	ERBB2
49	Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. (7523546)	Stieber P.... Meier W.	1994	ENO2, KRT19
50	Demonstration of gene amplification in urinary bladder cancer by fluorescent in situ hybridization (FISH) (7511290)	Sauter G.... Waldman F.	1993	ERBB2, EGFR, CCND1

Genes related to urinary bladder cancer according to GeneCards:

(show top 50)    (show all 139)

id	Symbol	Description	Score	GeneCards Section Context
1	CCND1	cyclin D1	11.0	Publications
2	TP53	tumor protein p53	11.0	Publications
3	LOC100270680	uncharacterized LOC100270680	11.0	Publications
4	TMEM129	transmembrane protein 129	11.0	Publications
5	UCA1	urothelial cancer associated 1 (non-protein coding)	11.0
6	HINT1	histidine triad nucleotide binding protein 1	11.0	Publications
7	UPK2	uroplakin 2	11.0
8	PTCRA	pre T-cell antigen receptor alpha	11.0
9	BLCAP	bladder cancer associated protein	11.0
10	TBRG1	transforming growth factor beta regulator 1	11.0
11	CYP2D7P1	cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1	11.0
12	UPK3A	uroplakin 3A	11.0
13	C5orf4	chromosome 5 open reading frame 4	11.0
14	SLC14A1	solute carrier family 14 (urea transporter), member 1 (Kidd blood group)	11.0	Publications
15	UPK1B	uroplakin 1B	11.0
16	SNX16	sorting nexin 16	11.0	Publications
17	GSTA3	glutathione S-transferase alpha 3	11.0
18	FGF4	fibroblast growth factor 4	11.0	Publications
19	FGF3	fibroblast growth factor 3	11.0	Publications
20	TACC3	transforming, acidic coiled-coil containing protein 3	11.0	Publications
21	ZNF135	zinc finger protein 135	11.0	Disorders
22	ARHGDIB	Rho GDP dissociation inhibitor (GDI) beta	11.0
23	ELAVL3	ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu antigen C)	11.0
24	SLBP	stem-loop binding protein	11.0	Publications
25	PSCA	prostate stem cell antigen	11.0	Publications
26	POLG2	polymerase (DNA directed), gamma 2, accessory subunit	11.0	Publications
27	ZNF77	zinc finger protein 77	11.0
28	IDH1	isocitrate dehydrogenase 1 (NADP+), soluble	11.0	Publications
29	PRDX2	peroxiredoxin 2	11.0	Publications
30	PEBP1	phosphatidylethanolamine binding protein 1	11.0	Publications
31	NAT1	N-acetyltransferase 1 (arylamine N-acetyltransferase)	11.0	Publications, UniProt Related
32	TEP1	telomerase-associated protein 1	11.0	Publications
33	HYAL1	hyaluronoglucosaminidase 1	11.0
34	E2F3	E2F transcription factor 3	11.0	Publications
35	KRT1	keratin 1	11.0	Publications
36	SERPINB3	serpin peptidase inhibitor, clade B (ovalbumin), member 3	11.0
37	SPINK1	serine peptidase inhibitor, Kazal type 1	11.0	Publications
38	WIF1	WNT inhibitory factor 1	11.0	Publications
39	WNT1	wingless-type MMTV integration site family, member 1	11.0	Publications
40	COTL1	coactosin-like 1 (Dictyostelium)	11.0	Publications
41	CD27	CD27 molecule	11.0	Publications
42	CEACAM1	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)	11.0	Publications
43	KRT20	keratin 20	11.0	Publications
44	GSTA4	glutathione S-transferase alpha 4	11.0
45	KRT19	keratin 19	11.0	Publications
46	GSTA2	glutathione S-transferase alpha 2	11.0
47	GLI1	GLI family zinc finger 1	11.0	Publications
48	IGFBP7	insulin-like growth factor binding protein 7	11.0	Publications
49	SKP2	S-phase kinase-associated protein 2, E3 ubiquitin protein ligase	11.0	Publications
50	RARG	retinoic acid receptor, gamma	11.0

Pathways related to urinary bladder cancer according to GeneDecks:

(show top 50)    (show all 266)

id	Pathway	Score	Top Affiliating Genes
1	Signal transduction_PTEN pathway41	10.4	IGF1R, PCNA
2	Transcription P53 signaling pathway10	10.2	VEGFA, CDKN2A, MAPK8, TP53
3	Small cell lung cancer20	10.0	RB1, E2F3, SKP2, PTGS2, TP53, CCND1
4	Akt Signaling36	10.0	FGFR3, IL2, MDM2, TBRG1, IGF1R, CCND1
5	Cell Cycle / Checkpoint Control3	9.8	CCND1, CCNE1, MDM2, GSTP1, TP53, TP63
6	DNA damage ATM/ATR regulation of G1/S checkpoint10	9.7	MYC, CCNE1, CDK4, CHEK2, MDM2
7	Glioma Invasiveness36	9.7	PLAU, FGF4, CD44, FGF2, TBRG1, PLAUR
8	G1-S Phase Transition36	9.7	E2F3, TGFB1, RB1, CDKN1A, TP53, CCND1
9	Cell cycle ESR1 regulation of G1/S transition10	9.6	CDKN1A, JUN, MYC, RB1, CDKN1B, CDK4
10	Cell cycle_ESR1 regulation of G1/S transition41	9.6	MAPK1, CDK4, CDKN1B, CDKN1A, JUN, MYC
11	Colorectal cancer20	9.4	BRAF, MAPK8, TGFB1
12	Cell cycle20	9.4	MYC, RB1, PCNA, CHEK2, CDKN1A, CDKN2B
13	Non-small cell lung cancer20	9.3	E2F3, TGFA, EGF, ERBB2, HRAS, MAPK1
14	Transcription_P53 signaling pathway41	9.2	ERCC2, TP53, NFKB1, HSPB1, MAPK8, MDM2
15	Chronic myeloid leukemia20	8.9	BRAF, MYC, CDKN1A, CDKN1B, CDKN2A, CDK4
16	Signal transduction PTEN pathway10	8.8	EGF, PCNA, MAPK1, HRAS, CASP3, IGF1R
17	Glioblastoma Multiforme36	8.8	RB1, BRAF, CDKN1A, CDKN1B, CDK4, MGMT
18	Pathway_PA16598005034	8.6	MAPK1, FGFR3, FGFR1, JUN, MYC, BRAF
19	Breast Cancer Regulation by Stathmin136	8.6	FGF2, FGF4, FGFR3, CCNE1, IGF1R, ERBB2
20	Telomerase Components in Cell Signaling36	8.6	FGFR1, RB1, MYC, FGF2, FGF4, FLT1
21	Glioma20	8.2	CDK4, MDM2, MAPK1, CCND1, IGF1R, HRAS
22	14-3-3 Induced Intracellular Signaling36	7.9	IGF1R, FGFR3, MAPK1, JUN, MAPK8, HRAS
23	Endothelin-1 Signaling Pathway36	7.9	EGFR, ERBB2, HRAS, MYC, FLT1, IGF1R
24	Prostate cancer20	7.6	MAPK1, CCNE1, CCND1, IGF1R, HRAS, ERBB2
25	Development_EGFR signaling pathway41	7.6	EGFR, ERBB2, MAPK1, JUN, MMP2, MMP9
26	Melanoma20	7.5	RB1, BRAF, CDKN1A, E2F3, EGFR, CDKN2A
27	Ras Pathway36	7.5	FGFR3, JUN, FLT1, FGF2, FGF4, FGFR1
28	Rac1 Pathway36	7.4	IL2, TGFB1, EGF, TBRG1, FGFR1, HRAS
29	P2Y Receptor Signaling36	7.3	JUN, MYC, FGF2, FGF3, FGF4, FGFR3
30	p53 Mediated Apoptosis36	7.3	CHEK2, BAX, FLT1, FGF2, FGF4, FGFR1
31	Mitochondrial Apoptosis36	7.2	CHEK2, EGF, EGFR, TGFA, TGFB1, TBRG1
32	Bladder cancer20	7.2	E2F3, CDKN1A, RASSF1, MYC, CDKN2A, CDK4
33	ILK Signaling36	7.2	TGFA, EGFR, EGF, TBRG1, PTGS2, ERBB2
34	Nanog in Mammalian ESC Pluripotency36	7.1	EGFR, EGF, HRAS, TBRG1, BRAF, FLT1
35	Cellular Apoptosis Pathway36	7.0	BAX, TGFA, TGFB1, EGFR, EGF, NFKB1
36	Rho Family GTPases36	6.9	IL1B, NFKB1, BAX, TBRG1, ERBB2, FGFR3
37	Colorectal Cancer Metastasis36	6.9	BRAF, MYC, BIRC5, BAX, CDKN1A, CDH1
38	Renin-Angiotensin Pathway36	6.6	PTGS2, IGF1R, MAPK1, MAPK8, FGFR3, FGFR1
39	ERK Signaling36	6.6	HRAS, MYC, TBRG1, ERBB2, BRAF, IGF1R
40	Estrogen Pathway36	6.3	CCND1, IGF1R, HRAS, ERBB2, TBRG1, SP1
41	p38 Signaling36	6.2	TP53, EGF, NFKB1, SP1, TGFB1, BAX
42	TGF-Beta Pathway36	6.1	BAX, JUN, CDH1, FLT1, FGF2, EGF
43	MAPK signaling pathway20	6.1	FGF4, FGFR1, BRAF, MYC, FGF3, JUN
44	GPCR Pathway36	6.1	HRAS, TGFA, MAPK8, EGFR, EGF, NFKB1
45	MAPK Family Pathway36	5.9	TGFB1, FGFR1, FGF2, IL1B, FGFR3, FGF4
46	Pancreatic Adenocarcinoma36	5.9	TBRG1, PTGS2, TP53, MMP9, FLT1, FGF2
47	MAPK Signaling36	5.6	FGFR1, IGF1R, FGFR3, IL1B, MAPK8, MAPK1
48	JAK-STAT Pathway36	5.3	MYC, BAX, JUN, FLT1, FGF2, FGF4
49	Molecular Mechanisms of Cancer36	5.3	RARB, MAPK8, MAPK1, CCNE1, CCND1, IGF1R
50	Pathways in cancer20	4.7	RB1, VEGFA, MYC, RARB, RASSF1, BIRC5

Compounds related to urinary bladder cancer according to GeneDecks:

(show top 50)    (show all 428)

id	Compound	Score	Top Affiliating Genes
1	threonine32	10.4	CDKN2B, CDKN1B, FGFR1, FGFR3, DAPK1, DAPK2
2	crcs32	10.0	RB1, BRAF, RASSF1, BIRC5, CDKN2A, CDH1
3	o6-methylguanine32	9.7	PCNA, BRAF, RARB, RASSF1, CDKN2B, CDKN2A
4	p00332	9.5	RB1, RASSF1, XRCC3, CDKN1B, CD44, CDH1
5	mitomycin c32	9.0	PCNA, RB1, BIRC5, XRCC3, MGMT, FGF2
6	n-(4-hydroxyphenyl)retinamide32	8.9	CNTN2, RB1, MYC, RARG, RARB, BAX
7	estradiol32 9 18 9	11.8	PCNA, RB1, RARB, BIRC5, LCP1, CDKN1B
8	n acetylcysteine32	8.4	PCNA, BIRC5, CLU, CHEK2, XRCC3, CDKN1A
9	sulforaphane32	8.3	RB1, JUN, CDKN1A, MGMT, GSTA1, GSTM1
10	adpribose32	8.3	PCNA, RB1, BIRC5, BAX, XRCC1, CDKN1A
11	trastuzumab32 34 9 9	11.3	BIRC5, CDKN1B, CDK4, MDM2, MAPK1, CCND1
12	flavopiridol32 9 9	10.2	RB1, VEGFA, BIRC5, BAX, CDKN1A, CDKN1B
13	vinorelbine32 9 9	10.1	VEGFA, MKI67, IGF1R, HSPB1, ERCC2, ERBB2
14	pge232	8.1	CDH1, FN1, FGF2, IL1RN, IGF1R, CTSD
15	creatinine32	8.1	PCNA, XRCC1, CD36, CDKN2A, CD44, CDH1
16	temozolomide32 9 9	10.0	PCNA, VEGFA, CHEK2, XRCC1, CDKN1A, CDKN2A
17	formaldehyde32 18	8.9	PCNA, RB1, CDKN1B, CD44, CDH1, MMP9
18	oxaliplatin32 34 9 9	10.7	VEGFA, BIRC5, XRCC1, CDKN1A, MGMT, GSTM1
19	bromodeoxyuridine32	7.6	CNTN2, PCNA, RB1, MYC, CDKN1A, CDKN1B
20	progesterone32 42 9 18 9	11.6	PCNA, RB1, BRAF, RARB, BIRC5, CLU
21	pdtc32	7.6	BIRC5, JUN, CDKN1A, MMP2, MMP9, IL1B
22	geldanamycin32 9 9	9.5	BRAF, VEGFA, BIRC5, JUN, CDKN1A, CDK4
23	vinblastine32 9 9	9.5	BIRC5, BAX, JUN, CDH1, MMP2, FN1
24	retinoid32	7.4	CNTN2, MYC, RARG, RARB, BAX, JUN
25	cysteine32	7.3	CNTN2, PCNA, NAT1, NAT2, RARB, CLU
26	methotrexate32 34 42 9 9	11.3	PCNA, RB1, NAT2, BIRC5, CDKN2B, CDKN1B
27	lactate32	7.3	PCNA, BIRC5, CLU, CD44, CDH1, MMP2
28	adriamycin32	7.2	RB1, MYC, BIRC5, CHEK2, BAX, CDKN1A
29	rapamycin32 42	8.1	RB1, BRAF, VEGFA, CHEK2, CDK4, FN1
30	gf 109203x32 42	8.1	VEGFA, JUN, CDKN1A, FN1, FGF2, MAPK8
31	imatinib32 34 9 9	9.8	BRAF, VEGFA, MYC, BIRC5, CEACAM1, CDKN1A
32	sb 20358032 42	7.8	RB1, BRAF, VEGFA, BIRC5, CDKN1A, CD36
33	phosphatidylinositol32	6.7	RB1, BRAF, MYC, BIRC5, CHEK2, BAX
34	irinotecan32 34 9 9	9.7	BRAF, VEGFA, BAX, XRCC1, CDKN1A, CDKN2A
35	arsenite32 18	7.7	CNTN2, PCNA, VEGFA, MYC, BIRC5, BAX
36	ly29400232	6.6	VEGFA, XPC, JUN, CDKN1B, CD44, CDH1
37	matrigel32	6.6	RB1, BRAF, VEGFA, CLU, CEACAM1, JUN
38	indomethacin32 9 9	8.6	PCNA, MYC, BIRC5, CDH1, FN1, IL1B
39	celecoxib32 42 34 9 18 9	11.5	PCNA, VEGFA, BIRC5, BAX, CDKN1A, CDKN1B
40	docetaxel32 34 9 9	9.3	VEGFA, MYC, BIRC5, CLU, BAX, CDKN1A
41	testosterone32 9 18 9	9.0	PCNA, RB1, RARB, BIRC5, CLU, LCP1
42	tamoxifen32 34 9 9	8.6	PCNA, VEGFA, MYC, BIRC5, CLU, BAX
43	vegf32	5.1	CNTN2, PCNA, BRAF, MYC, CLU, CEACAM1
44	paraffin32	5.0	PCNA, RB1, BRAF, VEGFA, MYC, BIRC5
45	herbimycin a32 42	5.7	MYC, JUN, CD36, CDK4, CDH1, MMP2
46	pd 98,05932	4.4	RB1, BRAF, MYC, BIRC5, BAX, JUN
47	thymidine32 18	5.4	CNTN2, PCNA, RB1, MYC, RARB, BIRC5
48	actinomycin d32	3.4	RB1, VEGFA, MYC, RARB, BIRC5, CLU
49	tyrosine32	3.3	CNTN2, RB1, BRAF, VEGFA, MYC, RARB
50	serine32	2.0	CNTN2, RB1, SERPINB3, BRAF, MYC, RARG

Cellular components related to urinary bladder cancer according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein kinase holoenzyme complex	GO:000307	10.1	CCND1, CCNE1, CDK4, CDKN1A
2	platelet alpha granule lumen	GO:031093	9.0	EGF, FN1, CLU, VEGFA, TGFB1
3	cell surface	GO:009986	8.7	ABCB1, TGFA, TGFB1, PEBP1, WNT1, PLAUR
4	nucleoplasm	GO:005654	7.8	E2F3, CCNE1, CCND1, CASP3, ERCC2, TP53
5	cytosol	GO:005829	7.1	CASP3, HSPB1, IDH1, CCND1, CCNE1, MAPK1
6	extracellular region	GO:005576	6.4	IFNA2, IFNG, SPINK1, CTSD, PLAU, PLAUR
7	extracellular space	GO:005615	5.8	IFNG, HYAL1, CTSD, PLAU, EGF, EGFR
8	cytoplasm	GO:005737	5.6	CTTN, SP1, DAPK2, DAPK1, PTGS2, TERT
9	nucleus	GO:005634	4.4	GLI1, HRAS, ERCC2, ERBB2, TP53, CASP3

Biological processes related to urinary bladder cancer according to GeneDecks:

(show top 50)    (show all 61)

id	Name	GO ID	Score	Top Affiliating Genes
1	glutathione metabolic process	GO:006749	10.7	IDH1, GSTP1, GSTA4, GSTA3, GSTA2, GSTA1
2	replicative senescence	GO:090399	10.5	TERT, TP53, CDKN2A, CDKN1A, CHEK2
3	neuron apoptotic process	GO:051402	10.5	GAPDH, TP63, TP53, CASP3, BAX, RB1
4	response to oxidative stress	GO:006979	10.3	PEBP1, PRDX2, KRT1, NFKB1, PTGS2, ERCC2
5	G1 phase of mitotic cell cycle	GO:000080	10.3	E2F3, SKP2, CCND1, CDK4, CDKN2A, CDKN1B
6	response to DNA damage stimulus	GO:006974	10.2	CCND1, CASP3, TP53, TOP2A, CDKN1A, XRCC3
7	response to organic nitrogen	GO:010243	10.2	PEBP1, PTGS2, CCND1, CCNE1, IL1RN, IL1B
8	G1/S transition of mitotic cell cycle	GO:000082	10.2	SKP2, CCND1, CCNE1, CDK4, CDKN2A, CDKN1B
9	release of cytochrome c from mitochondria	GO:001836	10.1	TP53, CASP3, JUN, BAX, CLU, MYC
10	xenobiotic metabolic process	GO:006805	10.1	CYP1A1, PTGS2, GSTP1, GSTM1, GSTA4, GSTA3
11	response to gamma radiation	GO:010332	10.1	TP53, IL1B, BAX, CHEK2, MYC
12	phosphatidylinositol-mediated signaling	GO:048015	10.1	TOP2A, ERBB2, IGF1R, MDM2, FGFR1, CDKN1B
13	cell cycle checkpoint	GO:000075	10.1	TP53, RB1, CHEK2, XPC, CDKN1A, CDKN1B
14	mitotic cell cycle	GO:000278	10.0	E2F3, TOP2A, SKP2, CCND1, CCNE1, CDK4
15	mitotic cell cycle G1/S transition checkpoint	GO:031575	10.0	TGFB1, HRAS, CDKN2B, RB1
16	negative regulation of phosphorylation	GO:042326	10.0	CDKN2A, CDKN1B, CDKN2B, CDKN1A
17	response to organic cyclic compound	GO:014070	10.0	PEBP1, PTGS2, CCND1, ENO2, IL1RN, CDKN1A
18	organ regeneration	GO:031100	10.0	WNT1, TGFB1, CCND1, CCNE1, MKI67, CDKN1A
19	positive regulation of apoptotic process	GO:043065	9.9	TOP2A, PTGS2, TP53, IL1B, MMP9, BAX
20	response to wounding	GO:009611	9.9	WNT1, PEBP1, POU5F1, TGFB1, CASP3, FN1
21	induction of apoptosis by intracellular signals	GO:008629	9.8	TP53, HRAS, CASP3, MAPK8, CDKN1A, BAX
22	Ras protein signal transduction	GO:007265	9.6	TP53, HRAS, MAPK1, FGF2, CDKN2A, CDKN1A
23	fibroblast growth factor receptor signaling pathway	GO:008543	9.6	CDKN1B, BRAF, FGF2, FGF3, FGF4, FGFR1
24	negative regulation of cyclin-dependent protein kinase activity	GO:045736	9.6	CDKN2A, CDKN1B, CDKN1A, CASP3
25	regulation of cell cycle	GO:051726	9.5	SKP2, PTGS2, FGF2, CDK4, JUN, BAX
26	positive regulation of protein phosphorylation	GO:001934	9.5	WNT1, TGFB1, ERBB2, HRAS, CCND1, IL1B
27	insulin receptor signaling pathway	GO:008286	9.4	HRAS, IGF1R, MAPK1, FGFR3, FGFR1, FGF4
28	positive regulation of ERK1 and ERK2 cascade	GO:070374	9.4	HRAS, IL1B, FGFR3, FGF4, FGF2, CD44
29	hyaluronan catabolic process	GO:030214	9.3	TGFB1, HYAL1, FGF2, CD44
30	protein autophosphorylation	GO:046777	9.3	EGFR, DAPK2, DAPK1, ERBB2, IGF1R, FGFR3
31	cell cycle arrest	GO:007050	9.3	HRAS, TP53, TBRG1, TGFB1, DBC1, IFNG
32	anti-apoptosis	GO:006916	9.3	PRDX2, TGFA, NFKB1, DAPK1, TERT, HSPB1
33	positive regulation of cell division	GO:051781	9.3	TGFB1, TGFA, IL1B, FGF4, FGF3, FGF2
34	positive regulation of fibroblast proliferation	GO:048146	9.3	WNT1, EGFR, CDK4, CDKN1A, JUN, MYC
35	negative regulation of cell growth	GO:030308	9.3	TGFB1, TP53, HYAL1, FGF2, CDKN2A, CDKN1B
36	induction of apoptosis	GO:006917	9.2	ERCC2, TP63, DAPK1, DAPK2, TGFB1, CASP3
37	angiogenesis	GO:001525	9.2	TGFA, TYMP, EGF, HSPB1, FGFR1, FN1
38	positive regulation of epithelial cell proliferation	GO:050679	9.1	TGFB1, TGFA, EGFR, ERBB2, HRAS, HYAL1
39	positive regulation of DNA replication	GO:045740	9.0	EGFR, HRAS, GLI1, IGF1R, JUN
40	negative regulation of cell proliferation	GO:008285	8.6	IGFBP7, HYAL1, HRAS, TP53, PTGS2, TBRG1
41	MAPK cascade	GO:000165	8.6	PEBP1, TGFB1, TGFA, EGFR, HRAS, MAPK1
42	positive regulation of MAP kinase activity	GO:043406	8.4	TGFB1, EGFR, EGF, ERBB2, FGFR1, FLT1
43	response to drug	GO:042493	8.4	CCND1, IFNG, PTGS2, ABCB1, TOP2A, TGFA
44	blood coagulation	GO:007596	8.1	PLAU, PLAUR, NOS2, EGF, TGFB1, TP53
45	epidermal growth factor receptor signaling pathway	GO:007173	8.1	MDM2, MAPK1, HRAS, ERBB2, EGF, EGFR
46	apoptotic process	GO:006915	7.8	KRT20, NFKB1, DAPK1, TP63, TP53, TRIO
47	positive regulation of transcription, DNA-dependent	GO:045893	7.7	TP53, TP63, SP1, NFKB1, EGF, TGFB1
48	negative regulation of apoptotic process	GO:043066	7.7	WNT1, FGF4, GSTP1, CD44, CDKN1B, CDKN1A
49	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.5	GLI1, HRAS, ERCC2, TP53, TP63, SP1
50	positive regulation of cell proliferation	GO:008284	6.7	E2F3, WNT1, FGF4, FGF3, FGF2, FLT1

Molecular functions related to urinary bladder cancer according to GeneDecks:

(show all 11)

id	Name	GO ID	Score	Top Affiliating Genes
1	glutathione transferase activity	GO:004364	10.5	GSTP1, GSTM1, GSTA4, GSTA3, GSTA2, GSTA1
2	cyclin-dependent protein kinase inhibitor activity	GO:004861	10.0	CASP3, CDKN2A, CDKN1B, CDKN2B, CDKN1A
3	transcription regulatory region DNA binding	GO:044212	9.6	WNT1, POU5F1, NFKB1, SP1, TP63, TP53
4	identical protein binding	GO:042802	9.0	ERBB2, TP53, TP63, DAPK2, SNX16, SKP2
5	enzyme binding	GO:019899	8.7	CSF3, TGFB1, TOP2A, EGFR, COTL1, PLAUR
6	protein homodimerization activity	GO:042803	8.6	TERT, PTGS2, SP1, NOS2, NFKB1, TOP2A
7	cytokine activity	GO:005125	8.4	CSF3, IFNG, IFNA2, IL2, IL1B, FGF2
8	protein heterodimerization activity	GO:046982	8.3	TGFB1, TOP2A, EGFR, TP53, ERBB2, ENO2
9	growth factor activity	GO:008083	7.8	CSF3, TGFB1, TGFA, TYMP, EGF, IL2
10	ATP binding	GO:005524	7.5	TEP1, TP53, TRIO, ERBB2, DAPK1, DAPK2
11	protein binding	GO:005515	2.2	IFNA2, TBRG1, DAPK1, SP1, SPINK1, CTTN